Weekly TP-HDFL in the Treatment of Advanced TCC

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Albumin-Bound Paclitaxel; Cisplatin; Fluorouracil; Paclitaxel

Criteria

Inclusion Criteria:

1. Pathology proven TCC Recurrent or metastatic TCC Muscle-invasive TCC

2. Measurable disease

3. Age>18

4. KPS>60﹪

5. Creatinine clearance>35ml/min,

6. AST/ALT < or = 3.5times upper limits of normal reference values

7. Bilirubin< or = 2.0 mg/dl

8. WBC > or = 4,000/mm3, PLT > or = 100,000/mm3

9. Written informed consent

Exclusion Criteria:

1. Previous systemic chemo is not allowed

2. TG <70mg/dl

3. CNS metastasis

4. Life expectancy less than 3 months